The new front line in advanced nasopharyngeal cancer

In reference to the article by Zhang et al . (1), we would like to congratulate the authors for reporting the first randomized controlled trial in the recurrent/metastatic nasopharyngeal cancer (NPC) setting. This study compares two widely used cisplatin containing doublet chemotherapy regimens and covers a great gap in the management of patients with metastatic or recurrent NPC. The results from this study with progression free survival (PFS) being the primary endpoint established the superiority of gemcitabine over infusional 5FU as the companion to the cisplatin backbone.